What is Precirix?
Founded in 2014 as a spin-off from the VUB, Precirix is dedicated to advancing cancer treatment through precision radiopharmaceuticals. The company leverages camelid single-domain antibodies, labeled with radioisotopes, to design and develop novel therapies aimed at extending and improving the lives of cancer patients. Precirix's pipeline includes one product candidate in Phase I/II clinical trials and two in advanced preclinical stages. The company's platform also supports a theragnostic approach, enabling patient selection via low-dose imaging followed by therapeutic treatment, and research into multiple isotopes, linker technologies, and combination therapies further broadens its therapeutic potential.
How much funding has Precirix raised?
Precirix has raised a total of $117.8M across 2 funding rounds:
Series A
$29.8M
Series B
$88M
Series A (2018): $29.8M with participation from Fournier-Majoie Foundation
Series B (2022): $88M led by Jeito, INKEF Capital, and Forbion
Key Investors in Precirix
Jeito
Jeito Capital is a global investment company focused on accelerating medical innovation with a patient-benefit driven approach, investing significant capital to build market leaders in therapeutic areas.
INKEF Capital
INKEF Capital is an Amsterdam-based venture capital firm that focuses on long-term collaboration and active support of innovative technology companies, particularly in Healthcare and Technology.
Forbion
Forbion is a global life sciences venture capital firm with a strong track record in guiding biotech and biopharmaceutical companies from early stage through clinical development, investing in innovative therapeutics.
What's next for Precirix?
The recent major strategic investment signals Precirix's transition into a scaling phase, likely focusing on advancing its lead candidates through clinical development and expanding its platform capabilities. This capital infusion is expected to accelerate the progression of its precision radiopharmaceutical programs, potentially leading to pivotal trials and eventual market entry. The company's focus on theragnostics and its broad pipeline suggest a strategic approach to addressing diverse oncology needs, positioning it for significant impact in the precision medicine landscape.
See full Precirix company page
